AC Immune SA (ACIU) stock
Close on Nov 17, 2026Market cap $214.68MP/E –Yield –
Earnings
AC Immune's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of AC Immune's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Mar 13, 2026before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | CHF 1.30M | – | -0.21 CHF | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 13, 2025before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 14, 2024before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 4, 2023before the open | – | – | -0.20 CHF | Release |
| Q4 FY2022ended Dec 31, 2022 | Apr 28, 2023before the open | – | – | -0.21 CHF | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 28, 2022before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 28, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 22, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
AC Immune's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total cash expenditurenon-GAAP | FY2025 | 75 – 85 | – | New | Mar 13, 2025 |
| total cash expenditurenon-GAAP | FY2026 | 55 – 65 | – | New | Mar 13, 2026 |
Guidance history
Every forecast AC Immune put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Mar 13, 2026 | total cash expenditure | FY2026 | 55 – 65 | New |
| Mar 13, 2025 | total cash expenditure | FY2025 | 75 – 85 | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases AC Immune filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?